KMT2A and leukemia: In conclusion, our present study demonstrates that prolonged exposure to a clinically relevant low‐dose of the DNA methyltransferase inhibitor decitabine significantly, but mildly delays leukemia progression in MLL‐rearranged ALL xenograft mouse models.